| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/29/2011 | CA2793750A1 Method and compositions to induce apoptosis of tumoral cells expressing shh |
| 09/29/2011 | CA2792663A1 Novel glucagon analogues |
| 09/29/2011 | CA2792470A1 Transdermal administration of peptides |
| 09/28/2011 | EP2369014A1 Compositions and methods for characterizing, regulating, diagnosing and treating cancer |
| 09/28/2011 | EP2369005A1 Biological active proteins having increased in vivo and/or in vitro stability |
| 09/28/2011 | EP2368999A1 Bone targeted alkaline phosphatase, kits and methods of use thereof |
| 09/28/2011 | EP2368988A1 Modulation of Glucocorticoid Receptor Expression |
| 09/28/2011 | EP2368984A1 Plasminogen activators having reduced lysine binding capacity |
| 09/28/2011 | EP2368983A2 Recombinant human factor IX and use thereof |
| 09/28/2011 | EP2368909A1 GLP-1 analog fusion proteins |
| 09/28/2011 | EP2368908A2 Anti- angiogenic compounds |
| 09/28/2011 | EP2368906A1 Fas associated factor 1 |
| 09/28/2011 | EP2368902A2 Insulin and IGF-1 receptor agonists and antagonists |
| 09/28/2011 | EP2368901A1 Peptidomimetic protease inhibitors |
| 09/28/2011 | EP2368900A2 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 09/28/2011 | EP2368898A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 09/28/2011 | EP2368878A1 Peptidomimetic protease inhibitors |
| 09/28/2011 | EP2368877A1 Chiral intermediates for the preparation of peptidomimetic protease inhibitors |
| 09/28/2011 | EP2368579A1 Transglutaminase mediated conjugation of peptides |
| 09/28/2011 | EP2368567A1 Non-neurotoxic plasminogen activating factors for treating strokes |
| 09/28/2011 | EP2368566A1 Interleukin 21 and tyrosine kinase inhibitor combination therapy |
| 09/28/2011 | EP2368565A1 Enrichment of pre-beta high density lipoproteins |
| 09/28/2011 | EP2368564A1 Pharmaceutical composition for acute phase protein targeted treatment of acute and chronic dysregulated inflammatory diseases or conditions |
| 09/28/2011 | EP2368563A1 Pharmaceutical composition containing GHRP-6 or GHRP-2 or hexarelin to prevent and eliminate fibrosis and other pathological deposits in tissues |
| 09/28/2011 | EP2368562A1 Compositions and methods for inducing melanogenesis in a subject |
| 09/28/2011 | EP2368561A1 Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| 09/28/2011 | EP2368431A1 Immunostimulatory G,U-containing oligoribonucleotides |
| 09/28/2011 | EP2368121A1 Method to select animals with a high capacity of embryo production |
| 09/28/2011 | EP2368114A2 Prediction and prevention of preeclampsia |
| 09/28/2011 | EP2367845A1 Lantibiotic carboxyamide derivatives with enhanced antibacterial activity |
| 09/28/2011 | EP2367842A1 Hmg-coa reductase derived peptide and cosmetic or pharmaceutical composition containing same |
| 09/28/2011 | EP2367565A1 Methods for the treatment and the prognostic assessment of malignant pleural mesothelioma. |
| 09/28/2011 | EP2367564A1 Norrin in the treatment of diseases associated with an increased tgf-beta activity |
| 09/28/2011 | EP2367563A1 Method of modulating hsf-1 |
| 09/28/2011 | EP2367562A1 Glycan-specific analytical tools |
| 09/28/2011 | EP2367561A1 Compositions and methods for treatment of celiac disease |
| 09/28/2011 | EP2367555A2 Regenerating and enhancing development of muscle tissue |
| 09/28/2011 | EP2367527A2 Implantable ocular drug delivery device and methods |
| 09/28/2011 | EP2367432A1 Infarct area perfusion-improving compositions and methods of vascular injury repair |
| 09/28/2011 | EP2208735B1 Food material for promoting the differentiation of osteoblast and inhibiting the differentiation of osteoclast |
| 09/28/2011 | EP2041159B1 Macrocyclic compounds as antiviral agents |
| 09/28/2011 | EP2040734B1 Antisecretory protein for use in the treatment of compartment syndrome |
| 09/28/2011 | EP1945201B1 Calcium receptor activator |
| 09/28/2011 | EP1864131B1 Natural ligand of g protein coupled receptor rcc356 and uses thereof |
| 09/28/2011 | EP1691825B1 Stabilized interferon liquid formulations |
| 09/28/2011 | EP1649041B1 Multimeric oxidoreductases |
| 09/28/2011 | EP1633865B1 New biological entities and the use thereof |
| 09/28/2011 | EP1572134B1 Protein s for use as a neuroprotective agent |
| 09/28/2011 | EP1536826B1 Igf-2 peptide for use in tolerogenic approaches for type i diabetes. |
| 09/28/2011 | EP1426054B1 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
| 09/28/2011 | EP1420809B1 Use of cyclopenta[g]quinazoline derivatives for treating cancer |
| 09/28/2011 | EP1420800B1 Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at 4) receptor activity |
| 09/28/2011 | EP1355669B1 Augmented cognitive training |
| 09/28/2011 | EP1353684B8 Use of inhibitors of dipeptidypeptidase iv (ec 3.3.14.5) and aminopeptidase n (ec 3.4.11.2) for the treatment of neurodegeneration induced by ischaemia |
| 09/28/2011 | EP1144613B1 Methods for making proteins containing free cysteine residues |
| 09/28/2011 | EP0777732B1 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| 09/28/2011 | CN1897951B Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune |
| 09/28/2011 | CN1732259B Method of degrading hardly degradable protein |
| 09/28/2011 | CN1346369B Method and compositions for the prevention and treatment of anamia |
| 09/28/2011 | CN102203290A Molecular marker for cancer stem cell |
| 09/28/2011 | CN102203258A TGF-b antagonist multi-target binding proteins |
| 09/28/2011 | CN102203245A Peptidomimetic macrocycles |
| 09/28/2011 | CN102203130A Glp-1 derivative and application thereof |
| 09/28/2011 | CN102203128A Use of inhibitors of plac8 activity for the modulation of adipogenesis |
| 09/28/2011 | CN102203126A Methods for preparing purified polypeptide compositions |
| 09/28/2011 | CN102203124A Amyloid ss peptide analogues, oligomers thereof, processes for preparing and compositions comprising said analogues or oligomers, and their uses |
| 09/28/2011 | CN102203118A Peptide antagonist of interleukin-15 activity |
| 09/28/2011 | CN102202736A Drug for treating infections |
| 09/28/2011 | CN102202690A Oncostatin m as promoter of immunostimulatory activity of human epithelial cells |
| 09/28/2011 | CN102202684A Method for the treatment of hemophilia |
| 09/28/2011 | CN102202683A Treating diabetes melitus using insulin injections with less than daily injection frequency |
| 09/28/2011 | CN102202682A Aqueous composition containing follicle-stimulating hormone |
| 09/28/2011 | CN102202681A Neuropeptide-2-receptor (y-2r) agonists and uses thereof |
| 09/28/2011 | CN102202680A Use of stem cells to prevent neuronal dieback |
| 09/28/2011 | CN102202679A Cycloundecadepsipeptide compounds and use of said compounds as a medicament |
| 09/28/2011 | CN102202678A CXCR4 receptor compounds |
| 09/28/2011 | CN102202677A Agents and methods for treatment of pain |
| 09/28/2011 | CN102202676A Dna-directed customization of analgesic compounds as a therapeutic modality |
| 09/28/2011 | CN102202674A Multilayered blood product |
| 09/28/2011 | CN102202662A Agent for treatment of diabetes |
| 09/28/2011 | CN102202647A Long term drug delivery devices with polyurethane-based polymers and their manufacture |
| 09/28/2011 | CN102202645A Implantable device for the delivery of octreotide and methods of use thereof |
| 09/28/2011 | CN102199615A cDNA sequence coding fibrinolysin, amino acid sequence and applications of sequences |
| 09/28/2011 | CN102199608A Efficient expression of pinellia ternate agglutinin (PTA) in bombyx mori reactor |
| 09/28/2011 | CN102199587A Functional mutant of human plasminogen, its preparation method and application |
| 09/28/2011 | CN102199584A Antithrombotic enzyme Eupolytinl from Eupolyphaga sinensis Walker and gene and application thereof |
| 09/28/2011 | CN102199572A Preparation method and purpose of mitofilin gene knockout mice model |
| 09/28/2011 | CN102199218A Fusion protein of Her2 antibody and interleukin 2 and application thereof |
| 09/28/2011 | CN102199216A New dendritic cell co-stimulatory molecules |
| 09/28/2011 | CN102199215A MAPWA fusion antibacterial peptide, preparation method and application thereof |
| 09/28/2011 | CN102199206A Insulin analogue having quick response and stability under acidic condition and preparation thereof |
| 09/28/2011 | CN102199199A Membrane localization staphylococcal enterotoxin A and gene sequence thereof |
| 09/28/2011 | CN102199197A Polypeptides with function of self-assembled potassium channel and its application |
| 09/28/2011 | CN102199196A Gene engineering antibacterial peptide and preparation method and application thereof |
| 09/28/2011 | CN102198272A Medicinal composition for promoting fracture union and repairing injured nerves |
| 09/28/2011 | CN102198266A Cancer antigens based on tumor suppressor gene WT1 product |
| 09/28/2011 | CN102198265A Method for degrading streptococcus suis biofilm by applying phage lyase |
| 09/28/2011 | CN102198264A Beta-defensin 15 of specific antibacterial peptides of rat epididymis and application thereof |
| 09/28/2011 | CN102198263A Application of ipomoea batatas Sporamin protein in preparation of medicines for treating and preventing tumours and health products |
| 09/28/2011 | CN102198103A Stable exenatide sustained-release microsphere preparation and preparation method thereof |